Real-world data on two-drug combo for hard-to-treat hodgkin lymphoma
NCT ID NCT07145125
First seen Nov 21, 2025 · Last updated Jun 22, 2026 · Updated 28 times
Summary
This study looked at 222 adults with Hodgkin lymphoma that had returned or not responded to first treatment. Researchers wanted to see how well the combination of brentuximab vedotin and bendamustine worked in everyday medical practice. They measured how long patients stayed free of progression and overall survival, along with side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY HODGKIN LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CH de la Côte Basque, service Hématologie Clinique
Bayonne, France
-
CHU de Bordeaux, service Hématologie Clinique et Thérapie cellulaire
Bordeaux, France
-
CHU de Caen, service Hématologie Clinique
Caen, France
-
CHU de Toulouse, service Hématologie Clinique
Toulouse, France
-
Institut Paoli Calmettes, service Hématologie Clinique
Marseille, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
brentuximab vedotin and bendamustine
What this could lead to
If results are positive, this could confirm a useful treatment option for people whose Hodgkin lymphoma has come back or not responded to initial therapy.
What could go wrong
This is a real-world observational study, not a controlled trial, so results may be less reliable. The combination also has known side effects like nerve damage and low blood counts.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.